<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00948896</url>
  </required_header>
  <id_info>
    <org_study_id>H9926-33953</org_study_id>
    <secondary_id>NIH P01HD059454</secondary_id>
    <secondary_id>2009-077</secondary_id>
    <secondary_id>HS-580</secondary_id>
    <secondary_id>686/ESR/NDA/DID-11/2009</secondary_id>
    <secondary_id>H9926-33953 and 10-01489</secondary_id>
    <nct_id>NCT00948896</nct_id>
  </id_info>
  <brief_title>Chemopreventive Therapy for Malaria in Ugandan Children</brief_title>
  <acronym>PROMOTE-Chemop</acronym>
  <official_title>A Randomized Controlled Trial of Monthly Dihydroartemisinin-piperaquine Versus Monthly Sulfadoxine-pyrimethamine Versus Daily Trimethoprim-sulfamethoxazole Versus No Therapy for the Prevention of Malaria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Young African children living in high transmission areas suffer the greatest burden of
      malaria. In most African countries, such as Uganda, the only current preventive measure
      against malaria in high transmission settings is the use of insecticide treated bednets
      (ITNs). Preliminary data show that even in the setting of ITN use, young children living in a
      high transmission setting suffer almost 4 episodes of clinical malaria per year, highlighting
      the need for new preventive strategies. Chemopreventive strategies offer a potential means of
      reducing the burden of malaria among young children living in a high transmission setting.
      This study will compare the efficacy and safety of 3 promising chemopreventive strategies
      (monthly dihydroartemisinin-piperaquine, monthly sulfadoxine-pyrimethamine, daily
      trimethoprim-sulfamethoxazole) with the current standard of no chemoprevention and will be
      conducted in two distinct patient populations: 1) HIV-unexposed children (HIV-uninfected
      children born to HIV-uninfected mothers) and 2) HIV-exposed children (HIV-uninfected children
      born to HIV-infected mothers). The intervention will begin in HIV-unexposed children when
      they reach 6 months of age, the time at which the incidence of malaria begins to increase,
      and will be continued until the children reach 24 months of age, which prior data suggest is
      when the incidence of malaria begins to decline due to the development of semi-immunity. In
      addition, study participants will be followed for one additional year following
      chemopreventive therapy to examine for &quot;rebound&quot; in the incidence of malaria following our
      intervention. HIV-exposed children will begin the intervention when they have completed
      breastfeeding and have been confirmed to remain HIV-uninfected. The intervention will
      continue until study participants reach 24 months of age and then the study participants will
      be followed for an additional year to examine for rebound in the incidence of malaria. It is
      anticipated that the results of this study will provide valuable comparative data on the
      effect of different chemopreventive strategies on malaria incidence in two distinct patient
      populations at high risk for malaria. In addition it is anticipated the results of this study
      will provide insight into the development of naturally acquired antimalarial immunity in the
      setting of chemopreventive therapy that will differ in terms of the drug regimens, the age at
      which the intervention is started, and the HIV status of the mothers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Convenience sampling will be used to enroll a cohort of 600 HIV-uninfected infants between
      the ages of 4-5 months of age according to the following strata based on the mother's HIV
      status: 1) 200 HIV-exposed infants born to HIV-infected mothers, and 2) 400 HIV-unexposed
      infants born to HIV-uninfected mothers. Potential study participants will be identified from
      the Tororo District Hospital Antenatal Clinic and surrounding clinics providing routine
      pediatric care. Potential study participants less than 6 months of age and their
      parents/guardians will be referred to our study clinic for screening. Eligible children will
      be enrolled when they reach 4-5 months of age and followed until the age of 36 months for all
      their routine medical care at our designated study clinic. All mother-child pairs will
      receive 2 long lasting ITNs at enrollment and, as available, a basic care package including a
      safe water vessel, multivitamins and condoms. HIV-unexposed children will be randomized to
      one of four chemoprevention arms when they reach 6 months of age. All HIV-exposed children
      born to HIV-infected mothers will be given TS prophylaxis and mothers will be encouraged to
      introduce food at 6 months of life and continue breastfeeding until 1 year of life, in
      accordance with Ugandan Ministry of Health (MOH) guidelines. HIV-exposed children will
      retested for HIV approximately every 60 days during breastfeeding and 6 weeks following
      cessation of breastfeeding. HIV-exposed children who remain HIV-uninfected following
      cessation of breastfeeding will be randomized to one of four chemoprevention arms.
      HIV-exposed children who test positive for HIV during the course of the study (those who
      seroconvert during breastfeeding) will be excluded from the study and referred for
      appropriate care.

      During the follow-up period, all patients presenting to the clinic with a new episode of
      fever will undergo standard evaluation (history, physical examination and Giemsa-stained
      blood smear) for the diagnosis of malaria. Children diagnosed with uncomplicated malaria will
      be treated with AL and children diagnosed with complicated malaria will be treated with
      quinine in accordance with national guidelines. Response to antimalarial therapy will be
      assessed using standardized guidelines. All AL treatment failures occurring within 14 days of
      diagnosis will be treated with quinine in accordance with national guidelines. In the event
      that a patient fails quinine therapy, therapy will be repeated with quinine plus clindamycin.
      Patients with complicated malaria who have contraindications to giving quinine will be
      treated with parenteral artesunate. All episodes diagnosed more than 14 days after a previous
      episode will be considered new episodes for treatment purposes. After two years of age,
      patients with uncomplicated malaria will have follow up visits on the days Antimalarial drugs
      are administered only (Day 0, 1, and 2). Routine assessments will be performed in the study
      clinic approximately every 30 days. Routine assessments will include review of study protocol
      with parents/guardians of study participants, assessment for any outside medical care,
      assessment for adherence to assigned chemopreventive therapy, a focused history and physical
      examination and routine blood smears for the detection of asymptomatic parasitemia. Routine
      phlebotomy will be performed approximately every 120 days for all study participants for CBC,
      glucose and ALT measurements.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incident Malaria Cases Per Person Year at Risk in HIV-unexposed Participants</measure>
    <time_frame>6 to 24 months of age</time_frame>
    <description>The incidence of malaria, defined as the number of incident episodes per time at risk, during the period the intervention was given (6-24 mo of age). Treatments within 14d of a prior episode were not considered incident events. Time at risk was from the day following the initiation of study drugs to the last day of observation, minus 14 d after each treatment for malaria.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incident Malaria Cases Per Person Year at Risk in HIV-exposed Participants</measure>
    <time_frame>Randomization to 24 months of age</time_frame>
    <description>The primary outcome was the incidence of malaria, defined as the number of incident episodes per time at risk, during the period the intervention was given. Treatments within 14 days of a prior episode were not considered incident events. Time at risk was from the day following the initiation of study drugs to the last day of observation, minus 14 days after each treatment for malaria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Any Adverse Events Defined as Severity Grade 3-4 That Are Possibly, Probably, or Definitely Related to Study Drugs</measure>
    <time_frame>Time from randomization until 24 months of age</time_frame>
    <description>NIH Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events published December, 2004</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rebound Incidence of Malaria Defined as the Number of Treatments for New Episodes of Malaria Per Time at Risk</measure>
    <time_frame>24 months to 36 months of age</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">600</enrollment>
  <condition>Malaria</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>trimethoprim-sulfamethoxazole (TS; TMP/SMX)</intervention_name>
    <description>daily dosing, 20mgTMP/100mgSMX tabs, 80mgTMP/400mgSMX tabs</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sulfadoxine-pyrimethamine (SP)</intervention_name>
    <description>monthly dosing given as a single dose, 500mg/25mg tabs</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dihydroartemisinin-piperaquine (DP)</intervention_name>
    <description>monthly dosing given once a day for 3 consecutive days, 40mg/320mg tabs</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 4 -5 months

          2. Confirmed HIV status of biological mother

          3. Negative HIV DNA PCR test at time of enrollment for infants born to HIV-infected
             mothers

          4. Infants born to HIV-infected mothers must be breastfeeding

          5. Residency within 30km of the study clinic

          6. Agreement to come to the study clinic for any febrile episode or other illness and
             avoid medications given outside the study protocol

          7. Provision of informed consent by parent/guardian

        Exclusion Criteria:

          1. History of allergy or sensitivity to TS, SP, or DP

          2. Active medical problem requiring in-patient evaluation at the time of screening

          3. Intention of moving more that 30km from the study clinic during the follow-up period

          4. Chronic medical condition (i.e. malignancy) requiring frequent medical attention

          5. Living in the same household as a previously enrolled study participant

          6. QTc interval &gt; 450 msec

          7. Other clinically significant ECG abnormalities such as arrhythmia, ischemia, or
             evidence of heart failure

          8. Family history of Long QT syndrome

          9. Current use of drugs that prolong the QT interval
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Months</minimum_age>
    <maximum_age>5 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diane V. Havlir, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>M. Grant Dorsey, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Moses R Kamya MBChB, MMed, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Makerere University; IDRC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IDRC Research Clinic -Tororo District Hospital</name>
      <address>
        <city>Tororo</city>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Uganda</country>
  </location_countries>
  <link>
    <url>http://www.muucsf.org/projects/chemo.html</url>
    <description>MU-UCSF Research Collaboration</description>
  </link>
  <results_reference>
    <citation>Osterbauer B, Kapisi J, Bigira V, Mwangwa F, Kinara S, Kamya MR, Dorsey G. Factors associated with malaria parasitaemia, malnutrition, and anaemia among HIV-exposed and unexposed Ugandan infants: a cross-sectional survey. Malar J. 2012 Dec 27;11:432. doi: 10.1186/1475-2875-11-432.</citation>
    <PMID>23270614</PMID>
  </results_reference>
  <results_reference>
    <citation>Ochong E, Tumwebaze PK, Byaruhanga O, Greenhouse B, Rosenthal PJ. Fitness Consequences of Plasmodium falciparum pfmdr1 Polymorphisms Inferred from Ex Vivo Culture of Ugandan Parasites. Antimicrob Agents Chemother. 2013 Sep;57(9):4245-4251. doi: 10.1128/AAC.00161-13. Epub 2013 Jun 24.</citation>
    <PMID>23796921</PMID>
  </results_reference>
  <results_reference>
    <citation>Marquez C, Okiring J, Chamie G, Ruel TD, Achan J, Kakuru A, Kamya MR, Charlebois ED, Havlir DV, Dorsey G. Increased morbidity in early childhood among HIV-exposed uninfected children in Uganda is associated with breastfeeding duration. J Trop Pediatr. 2014 Dec;60(6):434-41. doi: 10.1093/tropej/fmu045. Epub 2014 Aug 21.</citation>
    <PMID>25145704</PMID>
  </results_reference>
  <results_reference>
    <citation>Kamya MR, Kapisi J, Bigira V, Clark TD, Kinara S, Mwangwa F, Muhindo MK, Kakuru A, Aweeka FT, Huang L, Jagannathan P, Achan J, Havlir DV, Rosenthal PJ, Dorsey G. Efficacy and safety of three regimens for the prevention of malaria in young HIV-exposed Ugandan children: a randomized controlled trial. AIDS. 2014 Nov 28;28(18):2701-9. doi: 10.1097/QAD.0000000000000497.</citation>
    <PMID>25493596</PMID>
  </results_reference>
  <results_reference>
    <citation>Kapisi J, Bigira V, Clark T, Kinara S, Mwangwa F, Achan J, Kamya M, Soremekun S, Dorsey G. Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated malaria in the setting of three different chemopreventive regimens. Malar J. 2015 Feb 5;14:53. doi: 10.1186/s12936-015-0583-9.</citation>
    <PMID>25652127</PMID>
  </results_reference>
  <results_reference>
    <citation>Snyman K, Mwangwa F, Bigira V, Kapisi J, Clark TD, Osterbauer B, Greenhouse B, Sturrock H, Gosling R, Liu J, Dorsey G. Poor housing construction associated with increased malaria incidence in a cohort of young Ugandan children. Am J Trop Med Hyg. 2015 Jun;92(6):1207-13. doi: 10.4269/ajtmh.14-0828. Epub 2015 Apr 13.</citation>
    <PMID>25870429</PMID>
  </results_reference>
  <results_reference>
    <citation>Bigira V, Kapisi J, Clark TD, Kinara S, Mwangwa F, Muhindo MK, Osterbauer B, Aweeka FT, Huang L, Achan J, Havlir DV, Rosenthal PJ, Kamya MR, Dorsey G. Protective efficacy and safety of three antimalarial regimens for the prevention of malaria in young Ugandan children: a randomized controlled trial. PLoS Med. 2014 Aug 5;11(8):e1001689. doi: 10.1371/journal.pmed.1001689. eCollection 2014 Aug.</citation>
    <PMID>25093754</PMID>
  </results_reference>
  <results_reference>
    <citation>Sundell K, Jagannathan P, Huang L, Bigira V, Kapisi J, Kakuru MM, Savic R, Kamya MR, Dorsey G, Aweeka F. Variable piperaquine exposure significantly impacts protective efficacy of monthly dihydroartemisinin-piperaquine for the prevention of malaria in Ugandan children. Malar J. 2015 Sep 24;14:368. doi: 10.1186/s12936-015-0908-8.</citation>
    <PMID>26403465</PMID>
  </results_reference>
  <results_reference>
    <citation>Tumwebaze P, Conrad MD, Walakira A, LeClair N, Byaruhanga O, Nakazibwe C, Kozak B, Bloome J, Okiring J, Kakuru A, Bigira V, Kapisi J, Legac J, Gut J, Cooper RA, Kamya MR, Havlir DV, Dorsey G, Greenhouse B, Nsobya SL, Rosenthal PJ. Impact of antimalarial treatment and chemoprevention on the drug sensitivity of malaria parasites isolated from ugandan children. Antimicrob Agents Chemother. 2015;59(6):3018-30. doi: 10.1128/AAC.05141-14. Epub 2015 Mar 9.</citation>
    <PMID>25753626</PMID>
  </results_reference>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 27, 2009</study_first_submitted>
  <study_first_submitted_qc>July 28, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2009</study_first_posted>
  <results_first_submitted>April 30, 2015</results_first_submitted>
  <results_first_submitted_qc>July 7, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 4, 2015</results_first_posted>
  <last_update_submitted>October 26, 2015</last_update_submitted>
  <last_update_submitted_qc>October 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Grant Dorsey, M.D, Ph.D.</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Chemoprevention</keyword>
  <keyword>Uganda</keyword>
  <keyword>Malaria</keyword>
  <keyword>Trimethoprim-sulfamethoxazole</keyword>
  <keyword>Sulfadoxine-pyrimethamine</keyword>
  <keyword>Dihydroartemisinin-piperaquine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pyrimethamine</mesh_term>
    <mesh_term>Piperaquine</mesh_term>
    <mesh_term>Trimethoprim</mesh_term>
    <mesh_term>Sulfadoxine</mesh_term>
    <mesh_term>Dihydroartemisinin</mesh_term>
    <mesh_term>Artemisinins</mesh_term>
    <mesh_term>Fanasil, pyrimethamine drug combination</mesh_term>
    <mesh_term>Trimethoprim, Sulfamethoxazole Drug Combination</mesh_term>
    <mesh_term>Sulfamethoxazole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Convenience sampling was used to enroll a cohort of 600 infants 4–5 months of age from the Tororo District Hospital Maternal and Child Health clinic between June 2010 and July 2011.</recruitment_details>
      <pre_assignment_details>Of the 400 HIV-unexposed infants, 7 were excluded prior to randomization for inability to comply with study protocol.
Of the 200 HIV-exposed infants, 14 were excluded prior to randomization for the following reasons: 7 tested HIV positive; 3 unable to locate for &gt; 60 days; 2 withdrew informed consent; 1 died; 1 unable to comply with protocol.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>HIV-unexposed &amp; No Chemoprevention</title>
          <description>HIV-unexposed No chemoprevention was given</description>
        </group>
        <group group_id="P2">
          <title>HIV-unexposed &amp; SP</title>
          <description>HIV-unexposed sulfadoxine-pyrimethamine (SP): monthly dosing given as a single dose, 500mg/25mg tabs</description>
        </group>
        <group group_id="P3">
          <title>HIV-unexposed &amp; TS</title>
          <description>HIV-unexposed trimethoprim-sulfamethoxazole (TS; TMP/SMX): daily dosing, 20mgTMP/100mgSMX tabs, 80mgTMP/400mgSMX tabs</description>
        </group>
        <group group_id="P4">
          <title>HIV-unexposed &amp; DP</title>
          <description>HIV-unexposed dihydroartemisinin-piperaquine (DP): monthly dosing given once a day for 3 consecutive days, 40mg/320mg tabs</description>
        </group>
        <group group_id="P5">
          <title>HIV-exposed &amp; no Chemoprevention</title>
          <description>HIV-exposed No chemoprevention was given</description>
        </group>
        <group group_id="P6">
          <title>HIV-exposed &amp; SP</title>
          <description>HIV-exposed sulfadoxine-pyrimethamine (SP): monthly dosing given as a single dose, 500mg/25mg tabs</description>
        </group>
        <group group_id="P7">
          <title>HIV-exposed &amp; TS</title>
          <description>HIV-exposed trimethoprim-sulfamethoxazole (TS; TMP/SMX): daily dosing, 20mgTMP/100mgSMX tabs, 80mgTMP/400mgSMX tabs</description>
        </group>
        <group group_id="P8">
          <title>HIV-exposed &amp; DP</title>
          <description>HIV-exposed dihydroartemisinin-piperaquine (DP): monthly dosing given once a day for 3 consecutive days, 40mg/320mg tabs</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Randomization to 24 Months of Age</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="98"/>
                <participants group_id="P2" count="98"/>
                <participants group_id="P3" count="99"/>
                <participants group_id="P4" count="98"/>
                <participants group_id="P5" count="46"/>
                <participants group_id="P6" count="46"/>
                <participants group_id="P7" count="47"/>
                <participants group_id="P8" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="90"/>
                <participants group_id="P2" count="85"/>
                <participants group_id="P3" count="90"/>
                <participants group_id="P4" count="87"/>
                <participants group_id="P5" count="44"/>
                <participants group_id="P6" count="42"/>
                <participants group_id="P7" count="43"/>
                <participants group_id="P8" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="11"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="4"/>
                <participants group_id="P8" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Moved out of Study Area</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>24 Months of Age to 36 Months of Age</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="90"/>
                <participants group_id="P2" count="85"/>
                <participants group_id="P3" count="90"/>
                <participants group_id="P4" count="87"/>
                <participants group_id="P5" count="44"/>
                <participants group_id="P6" count="42"/>
                <participants group_id="P7" count="43"/>
                <participants group_id="P8" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="87"/>
                <participants group_id="P2" count="83"/>
                <participants group_id="P3" count="85"/>
                <participants group_id="P4" count="85"/>
                <participants group_id="P5" count="43"/>
                <participants group_id="P6" count="40"/>
                <participants group_id="P7" count="43"/>
                <participants group_id="P8" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Moved out of Study Area</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Convenience sampling was used to enroll a cohort of 600 infants 4–5 mo of age from the Tororo District Hospital Maternal and Child Health Clinic between June 2010 and July 2011. The baseline characteristics were taken at enrollment.</population>
      <group_list>
        <group group_id="B1">
          <title>HIV-unexposed &amp; no Chemoprevention</title>
          <description>HIV-unexposed No chemoprevention was given</description>
        </group>
        <group group_id="B2">
          <title>HIV-unexposed &amp; Monthly SP</title>
          <description>HIV-unexposed sulfadoxine-pyrimethamine (SP): monthly dosing given as a single dose, 500mg/25mg tabs</description>
        </group>
        <group group_id="B3">
          <title>HIV-unexposed &amp; Daily TS</title>
          <description>HIV-unexposed trimethoprim-sulfamethoxazole (TS; TMP/SMX): daily dosing, 20mgTMP/100mgSMX tabs, 80mgTMP/400mgSMX tabs</description>
        </group>
        <group group_id="B4">
          <title>HIV-unexposed &amp; Monthly DP</title>
          <description>HIV-unexposed dihydroartemisinin-piperaquine (DP): monthly dosing given once a day for 3 consecutive days, 40mg/320mg tabs</description>
        </group>
        <group group_id="B5">
          <title>HIV-exposed &amp; no Chemoprevention</title>
          <description>HIV-exposed No chemoprevention was given</description>
        </group>
        <group group_id="B6">
          <title>HIV-exposed &amp; Monthly SP</title>
          <description>HIV-exposed sulfadoxine-pyrimethamine (SP): monthly dosing given as a single dose, 500mg/25mg tabs</description>
        </group>
        <group group_id="B7">
          <title>HIV-exposed &amp; Daily TS</title>
          <description>HIV-exposed trimethoprim-sulfamethoxazole (TS; TMP/SMX): daily dosing, 20mgTMP/100mgSMX tabs, 80mgTMP/400mgSMX tabs</description>
        </group>
        <group group_id="B8">
          <title>HIV-exposed &amp; Monthly DP</title>
          <description>HIV-exposed dihydroartemisinin-piperaquine (DP): monthly dosing given once a day for 3 consecutive days, 40mg/320mg tabs</description>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="98"/>
            <count group_id="B2" value="98"/>
            <count group_id="B3" value="99"/>
            <count group_id="B4" value="98"/>
            <count group_id="B5" value="46"/>
            <count group_id="B6" value="46"/>
            <count group_id="B7" value="47"/>
            <count group_id="B8" value="47"/>
            <count group_id="B9" value="579"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Age in months at time of enrollment</description>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.4" spread="0.5"/>
                    <measurement group_id="B2" value="5.3" spread="0.5"/>
                    <measurement group_id="B3" value="5.4" spread="0.5"/>
                    <measurement group_id="B4" value="5.4" spread="0.5"/>
                    <measurement group_id="B5" value="4.8" spread="0.7"/>
                    <measurement group_id="B6" value="4.7" spread="0.7"/>
                    <measurement group_id="B7" value="4.8" spread="0.8"/>
                    <measurement group_id="B8" value="4.7" spread="0.8"/>
                    <measurement group_id="B9" value="5.2" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="48"/>
                    <measurement group_id="B4" value="52"/>
                    <measurement group_id="B5" value="22"/>
                    <measurement group_id="B6" value="21"/>
                    <measurement group_id="B7" value="27"/>
                    <measurement group_id="B8" value="25"/>
                    <measurement group_id="B9" value="287"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="46"/>
                    <measurement group_id="B5" value="24"/>
                    <measurement group_id="B6" value="25"/>
                    <measurement group_id="B7" value="20"/>
                    <measurement group_id="B8" value="22"/>
                    <measurement group_id="B9" value="292"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Slept under any bednet prior night</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="45"/>
                    <measurement group_id="B5" value="27"/>
                    <measurement group_id="B6" value="27"/>
                    <measurement group_id="B7" value="26"/>
                    <measurement group_id="B8" value="29"/>
                    <measurement group_id="B9" value="278"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="59"/>
                    <measurement group_id="B4" value="53"/>
                    <measurement group_id="B5" value="19"/>
                    <measurement group_id="B6" value="19"/>
                    <measurement group_id="B7" value="21"/>
                    <measurement group_id="B8" value="18"/>
                    <measurement group_id="B9" value="301"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Slept under ITN prior night</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="29"/>
                    <measurement group_id="B5" value="22"/>
                    <measurement group_id="B6" value="24"/>
                    <measurement group_id="B7" value="19"/>
                    <measurement group_id="B8" value="22"/>
                    <measurement group_id="B9" value="200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="72"/>
                    <measurement group_id="B4" value="69"/>
                    <measurement group_id="B5" value="24"/>
                    <measurement group_id="B6" value="22"/>
                    <measurement group_id="B7" value="28"/>
                    <measurement group_id="B8" value="25"/>
                    <measurement group_id="B9" value="379"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Stunted</title>
          <description>Length-for-age z-score &lt;-2</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="7"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="7"/>
                    <measurement group_id="B9" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="93"/>
                    <measurement group_id="B4" value="94"/>
                    <measurement group_id="B5" value="40"/>
                    <measurement group_id="B6" value="39"/>
                    <measurement group_id="B7" value="41"/>
                    <measurement group_id="B8" value="40"/>
                    <measurement group_id="B9" value="522"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Wasted</title>
          <description>Weight-for-age Z-score &lt; -2</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="4"/>
                    <measurement group_id="B9" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="94"/>
                    <measurement group_id="B2" value="91"/>
                    <measurement group_id="B3" value="92"/>
                    <measurement group_id="B4" value="93"/>
                    <measurement group_id="B5" value="46"/>
                    <measurement group_id="B6" value="42"/>
                    <measurement group_id="B7" value="46"/>
                    <measurement group_id="B8" value="43"/>
                    <measurement group_id="B9" value="547"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hemoglobin</title>
          <units>gm/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.7" spread="1.4"/>
                    <measurement group_id="B2" value="9.6" spread="1.8"/>
                    <measurement group_id="B3" value="9.9" spread="1.5"/>
                    <measurement group_id="B4" value="9.5" spread="1.5"/>
                    <measurement group_id="B5" value="10.1" spread="1.2"/>
                    <measurement group_id="B6" value="10.0" spread="1.4"/>
                    <measurement group_id="B7" value="10.1" spread="1.1"/>
                    <measurement group_id="B8" value="10.5" spread="1.5"/>
                    <measurement group_id="B9" value="9.8" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Positive thick blood smear</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="28"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="8"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="82"/>
                    <measurement group_id="B4" value="70"/>
                    <measurement group_id="B5" value="38"/>
                    <measurement group_id="B6" value="42"/>
                    <measurement group_id="B7" value="39"/>
                    <measurement group_id="B8" value="41"/>
                    <measurement group_id="B9" value="459"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Taking TS prophylaxis</title>
          <description>This measurement is only applicable for the HIV-exposed participants (n=186).</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">Only applicable for HIV-exposed participants</measurement>
                    <measurement group_id="B2" value="NA">Only applicable for HIV-exposed participants</measurement>
                    <measurement group_id="B3" value="NA">Only applicable for HIV-exposed participants</measurement>
                    <measurement group_id="B4" value="NA">Only applicable for HIV-exposed participants</measurement>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="7"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="9"/>
                    <measurement group_id="B9" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">Only applicable for HIV-exposed participants</measurement>
                    <measurement group_id="B2" value="NA">Only applicable for HIV-exposed participants</measurement>
                    <measurement group_id="B3" value="NA">Only applicable for HIV-exposed participants</measurement>
                    <measurement group_id="B4" value="NA">Only applicable for HIV-exposed participants</measurement>
                    <measurement group_id="B5" value="41"/>
                    <measurement group_id="B6" value="39"/>
                    <measurement group_id="B7" value="42"/>
                    <measurement group_id="B8" value="38"/>
                    <measurement group_id="B9" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age at time of randomization</title>
          <units>months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.0" lower_limit="6.0" upper_limit="6.5"/>
                    <measurement group_id="B2" value="6.0" lower_limit="6.0" upper_limit="6.5"/>
                    <measurement group_id="B3" value="6.0" lower_limit="6.0" upper_limit="6.3"/>
                    <measurement group_id="B4" value="6.0" lower_limit="6.0" upper_limit="6.5"/>
                    <measurement group_id="B5" value="10.0" lower_limit="6.0" upper_limit="18.0"/>
                    <measurement group_id="B6" value="9.3" lower_limit="6.5" upper_limit="18.8"/>
                    <measurement group_id="B7" value="11.6" lower_limit="6.2" upper_limit="18.7"/>
                    <measurement group_id="B8" value="10.3" lower_limit="6.5" upper_limit="20.0"/>
                    <measurement group_id="B9" value="6.0" lower_limit="6.0" upper_limit="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of follow-up</title>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="547" lower_limit="53" upper_limit="580"/>
                    <measurement group_id="B2" value="547" lower_limit="63" upper_limit="550"/>
                    <measurement group_id="B3" value="547" lower_limit="58" upper_limit="564"/>
                    <measurement group_id="B4" value="547" lower_limit="7" upper_limit="569"/>
                    <measurement group_id="B5" value="427" lower_limit="88" upper_limit="549"/>
                    <measurement group_id="B6" value="420" lower_limit="127" upper_limit="524"/>
                    <measurement group_id="B7" value="346" lower_limit="88" upper_limit="505"/>
                    <measurement group_id="B8" value="409" lower_limit="31" upper_limit="535"/>
                    <measurement group_id="B9" value="546" lower_limit="7" upper_limit="580"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Any Adverse Events Defined as Severity Grade 3-4 That Are Possibly, Probably, or Definitely Related to Study Drugs</title>
        <description>NIH Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events published December, 2004</description>
        <time_frame>Time from randomization until 24 months of age</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HIV-unexposed &amp; no Chemoprevention</title>
            <description>HIV-unexposed No chemoprevention was given</description>
          </group>
          <group group_id="O2">
            <title>HIV-unexposed &amp; Monthly SP</title>
            <description>HIV-unexposed sulfadoxine-pyrimethamine (SP): monthly dosing given as a single dose, 500mg/25mg tabs</description>
          </group>
          <group group_id="O3">
            <title>HIV-unexposed &amp; Daily TS</title>
            <description>HIV-unexposed trimethoprim-sulfamethoxazole (TS; TMP/SMX): daily dosing, 20mgTMP/100mgSMX tabs, 80mgTMP/400mgSMX tabs</description>
          </group>
          <group group_id="O4">
            <title>HIV-unexposed &amp; Monthly DP</title>
            <description>HIV-unexposed dihydroartemisinin-piperaquine (DP): monthly dosing given once a day for 3 consecutive days, 40mg/320mg tabs</description>
          </group>
          <group group_id="O5">
            <title>HIV-exposed &amp; no Chemoprevention</title>
            <description>HIV-exposed No chemoprevention was given</description>
          </group>
          <group group_id="O6">
            <title>HIV-exposed &amp; Monthly SP</title>
            <description>HIV-exposed sulfadoxine-pyrimethamine (SP): monthly dosing given as a single dose, 500mg/25mg tabs</description>
          </group>
          <group group_id="O7">
            <title>HIV-exposed &amp; Daily TS</title>
            <description>HIV-exposed trimethoprim-sulfamethoxazole (TS; TMP/SMX): daily dosing, 20mgTMP/100mgSMX tabs, 80mgTMP/400mgSMX tabs</description>
          </group>
          <group group_id="O8">
            <title>HIV-exposed &amp; Monthly DP</title>
            <description>HIV-exposed dihydroartemisinin-piperaquine (DP): monthly dosing given once a day for 3 consecutive days, 40mg/320mg tabs</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Any Adverse Events Defined as Severity Grade 3-4 That Are Possibly, Probably, or Definitely Related to Study Drugs</title>
          <description>NIH Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events published December, 2004</description>
          <units>incidence per person-year at risk</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="99"/>
                <count group_id="O4" value="98"/>
                <count group_id="O5" value="46"/>
                <count group_id="O6" value="46"/>
                <count group_id="O7" value="47"/>
                <count group_id="O8" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All grade 3-4 adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.159"/>
                    <measurement group_id="O2" value="1.415"/>
                    <measurement group_id="O3" value="0.914"/>
                    <measurement group_id="O4" value="0.611"/>
                    <measurement group_id="O5" value="1.214"/>
                    <measurement group_id="O6" value="1.478"/>
                    <measurement group_id="O7" value="0.659"/>
                    <measurement group_id="O8" value="0.678"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3-4 AEs possibly related to study drugs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No study drugs taken.</measurement>
                    <measurement group_id="O2" value="0.056"/>
                    <measurement group_id="O3" value="0.054"/>
                    <measurement group_id="O4" value="0.021"/>
                    <measurement group_id="O5" value="NA">No study drugs taken.</measurement>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0.062"/>
                    <measurement group_id="O8" value="0.097"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All serious adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.178"/>
                    <measurement group_id="O2" value="0.364"/>
                    <measurement group_id="O3" value="0.196"/>
                    <measurement group_id="O4" value="0.091"/>
                    <measurement group_id="O5" value="0.411"/>
                    <measurement group_id="O6" value="0.453"/>
                    <measurement group_id="O7" value="0.330"/>
                    <measurement group_id="O8" value="0.194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Elevated Temperature</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.542"/>
                    <measurement group_id="O2" value="0.546"/>
                    <measurement group_id="O3" value="0.393"/>
                    <measurement group_id="O4" value="0.323"/>
                    <measurement group_id="O5" value="0.431"/>
                    <measurement group_id="O6" value="0.532"/>
                    <measurement group_id="O7" value="0.206"/>
                    <measurement group_id="O8" value="0.174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.384"/>
                    <measurement group_id="O2" value="0.602"/>
                    <measurement group_id="O3" value="0.318"/>
                    <measurement group_id="O4" value="0.168"/>
                    <measurement group_id="O5" value="0.705"/>
                    <measurement group_id="O6" value="0.631"/>
                    <measurement group_id="O7" value="0.206"/>
                    <measurement group_id="O8" value="0.291"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thrombocytopenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.123"/>
                    <measurement group_id="O2" value="0.119"/>
                    <measurement group_id="O3" value="0.061"/>
                    <measurement group_id="O4" value="0.035"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0.118"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0.058"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Elevated aspartate aminotransferase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.048"/>
                    <measurement group_id="O2" value="0.056"/>
                    <measurement group_id="O3" value="0.041"/>
                    <measurement group_id="O4" value="0.021"/>
                    <measurement group_id="O5" value="0.039"/>
                    <measurement group_id="O6" value="0.020"/>
                    <measurement group_id="O7" value="0.041"/>
                    <measurement group_id="O8" value="0.039"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Elevated alanine aminotransferase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.027"/>
                    <measurement group_id="O2" value="0.028"/>
                    <measurement group_id="O3" value="0.027"/>
                    <measurement group_id="O4" value="0.021"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutropenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.021"/>
                    <measurement group_id="O2" value="0.042"/>
                    <measurement group_id="O3" value="0.014"/>
                    <measurement group_id="O4" value="0.007"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malnutrition</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0.020"/>
                    <measurement group_id="O6" value="0.020"/>
                    <measurement group_id="O7" value="0.021"/>
                    <measurement group_id="O8" value="0.039"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: Within HIV-unexposed participants, there is no difference in the incidence of all grade 3-4 adverse events per PYAR between the control arm and the monthly DP arm.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Negative Binomial Regression</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: Within HIV-unexposed participants, there is no difference in the incidence of elevated temperature adverse events per PYAR between the control arm and the monthly DP arm.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <p_value_desc>Monthly DP arm compared to No chemoprevention arm</p_value_desc>
            <method>Negative Binomial Regression</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: Within HIV-unexposed participants, there is no difference in the incidence of anemia adverse events per PYAR between the control arm and the monthly DP arm.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <p_value_desc>Monthly DP arm compared to No chemoprevention arm</p_value_desc>
            <method>Negative Binomial Regression</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: Within HIV-unexposed participants, there is no difference in the incidence of thrombocytopenia adverse events per PYAR between the control arm and the monthly DP arm.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>Monthly DP arm compared to No chemoprevention arm</p_value_desc>
            <method>Negative Binomial Regression</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: Within HIV-exposed participants, there is no difference in the incidence of all grade 3-4 adverse events per PYAR between the control arm and the monthly DP arm.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>Monthly DP arm compared with no chemoprevention arm.</p_value_desc>
            <method>Negative Binomial Regression</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: Within HIV-exposed participants, there is no difference in the incidence of anemia adverse events per PYAR between the control arm and the monthly DP arm</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>Monthly DP arm compared with no chemoprevention arm.</p_value_desc>
            <method>Negative Binomial Regression</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: Within HIV-exposed participants, there is no difference in the incidence of elevated temperature adverse events per PYAR between the control arm and the monthly DP arm</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>Monthly DP arm compared with the no chemoprevention arm.</p_value_desc>
            <method>Negative Binomial Regression</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: Within HIV-exposed participants, there is no difference in the incidence of anemia adverse events per PYAR between the control arm and the daily TS arm</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <p_value_desc>Daily TS arm compare with the no chemoprevention arm.</p_value_desc>
            <method>Negative Binomial Regression</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rebound Incidence of Malaria Defined as the Number of Treatments for New Episodes of Malaria Per Time at Risk</title>
        <time_frame>24 months to 36 months of age</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HIV-unexposed &amp; no Chemoprevention</title>
            <description>HIV-unexposed No chemoprevention was given</description>
          </group>
          <group group_id="O2">
            <title>HIV-unexposed &amp; Monthly SP</title>
            <description>HIV-unexposed sulfadoxine-pyrimethamine (SP): monthly dosing given as a single dose, 500mg/25mg tabs</description>
          </group>
          <group group_id="O3">
            <title>HIV-unexposed &amp; Daily TS</title>
            <description>HIV-unexposed trimethoprim-sulfamethoxazole (TS; TMP/SMX): daily dosing, 20mgTMP/100mgSMX tabs, 80mgTMP/400mgSMX tabs</description>
          </group>
          <group group_id="O4">
            <title>HIV-unexposed &amp; Monthly DP</title>
            <description>HIV-unexposed dihydroartemisinin-piperaquine (DP): monthly dosing given once a day for 3 consecutive days, 40mg/320mg tabs</description>
          </group>
          <group group_id="O5">
            <title>HIV-exposed &amp; no Chemoprevention</title>
            <description>HIV-exposed No chemoprevention was given</description>
          </group>
          <group group_id="O6">
            <title>HIV-exposed &amp; Monthly SP</title>
            <description>HIV-exposed sulfadoxine-pyrimethamine (SP): monthly dosing given as a single dose, 500mg/25mg tabs</description>
          </group>
          <group group_id="O7">
            <title>HIV-exposed &amp; Daily TS</title>
            <description>HIV-exposed trimethoprim-sulfamethoxazole (TS; TMP/SMX): daily dosing, 20mgTMP/100mgSMX tabs, 80mgTMP/400mgSMX tabs</description>
          </group>
          <group group_id="O8">
            <title>HIV-exposed &amp; Monthly DP</title>
            <description>HIV-exposed dihydroartemisinin-piperaquine (DP): monthly dosing given once a day for 3 consecutive days, 40mg/320mg tabs</description>
          </group>
        </group_list>
        <measure>
          <title>Rebound Incidence of Malaria Defined as the Number of Treatments for New Episodes of Malaria Per Time at Risk</title>
          <units>Incidence per person year at risk</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="83"/>
                <count group_id="O3" value="85"/>
                <count group_id="O4" value="85"/>
                <count group_id="O5" value="43"/>
                <count group_id="O6" value="40"/>
                <count group_id="O7" value="43"/>
                <count group_id="O8" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All incident episodes of malaria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.85"/>
                    <measurement group_id="O2" value="11.98"/>
                    <measurement group_id="O3" value="10.90"/>
                    <measurement group_id="O4" value="10.77"/>
                    <measurement group_id="O5" value="9.08"/>
                    <measurement group_id="O6" value="6.75"/>
                    <measurement group_id="O7" value="8.13"/>
                    <measurement group_id="O8" value="6.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complicated malaria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.046"/>
                    <measurement group_id="O2" value="0.132"/>
                    <measurement group_id="O3" value="0.046"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0.161"/>
                    <measurement group_id="O6" value="0.147"/>
                    <measurement group_id="O7" value="0.116"/>
                    <measurement group_id="O8" value="0.044"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All-cause hospital admissions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.046"/>
                    <measurement group_id="O2" value="0.452"/>
                    <measurement group_id="O3" value="0.091"/>
                    <measurement group_id="O4" value="0.023"/>
                    <measurement group_id="O5" value="0.459"/>
                    <measurement group_id="O6" value="0.318"/>
                    <measurement group_id="O7" value="0.186"/>
                    <measurement group_id="O8" value="0.089"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incident Malaria Cases Per Person Year at Risk in HIV-unexposed Participants</title>
        <description>The incidence of malaria, defined as the number of incident episodes per time at risk, during the period the intervention was given (6–24 mo of age). Treatments within 14d of a prior episode were not considered incident events. Time at risk was from the day following the initiation of study drugs to the last day of observation, minus 14 d after each treatment for malaria.</description>
        <time_frame>6 to 24 months of age</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HIV-unexposed &amp; no Chemoprevention</title>
            <description>HIV-unexposed No chemoprevention was given</description>
          </group>
          <group group_id="O2">
            <title>HIV-unexposed &amp; Monthly SP</title>
            <description>HIV-unexposed sulfadoxine-pyrimethamine (SP): monthly dosing given as a single dose, 500mg/25mg tabs</description>
          </group>
          <group group_id="O3">
            <title>HIV-unexposed &amp; Daily TS</title>
            <description>HIV-unexposed trimethoprim-sulfamethoxazole (TS; TMP/SMX): daily dosing, 20mgTMP/100mgSMX tabs, 80mgTMP/400mgSMX tabs</description>
          </group>
          <group group_id="O4">
            <title>HIV-unexposed &amp; Monthly DP</title>
            <description>HIV-unexposed dihydroartemisinin-piperaquine (DP): monthly dosing given once a day for 3 consecutive days, 40mg/320mg tabs</description>
          </group>
        </group_list>
        <measure>
          <title>Incident Malaria Cases Per Person Year at Risk in HIV-unexposed Participants</title>
          <description>The incidence of malaria, defined as the number of incident episodes per time at risk, during the period the intervention was given (6–24 mo of age). Treatments within 14d of a prior episode were not considered incident events. Time at risk was from the day following the initiation of study drugs to the last day of observation, minus 14 d after each treatment for malaria.</description>
          <units>Episode per person year at risk</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="99"/>
                <count group_id="O4" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6-24 mo. of Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.95"/>
                    <measurement group_id="O2" value="6.73"/>
                    <measurement group_id="O3" value="5.21"/>
                    <measurement group_id="O4" value="3.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6-11 mo. of Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.41"/>
                    <measurement group_id="O2" value="5.51"/>
                    <measurement group_id="O3" value="3.27"/>
                    <measurement group_id="O4" value="1.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12-24 mo. of Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.24"/>
                    <measurement group_id="O2" value="7.41"/>
                    <measurement group_id="O3" value="6.32"/>
                    <measurement group_id="O4" value="3.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The sample size was calculated to detect at least a 32% lower incidence of malaria in the DP arm compared to that in the TS arm. We assumed that the incidence of malaria would be 1.85 episodes per person-year with TS chemoprevention based on a prior cohort study in the same area, and thus we calculated that we would need to enroll 100 participants in each arm to detect our targeted protective efficacy with 80% power at 95% significance (two-sided), allowing for 10% loss to follow-up.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.57</p_value>
            <method>Negative Binomial Regression</method>
            <param_type>Protective Efficacy (%)</param_type>
            <param_value>7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-19</ci_lower_limit>
            <ci_upper_limit>28</ci_upper_limit>
            <estimate_desc>The no chemoprevention arm is the reference group.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The sample size was calculated to detect at least a 32% lower incidence of malaria in the DP arm compared to that in the TS arm. We assumed that the incidence of malaria would be 1.85 episodes per person-year with TS chemoprevention based on a prior cohort study in the same area, and thus we calculated that we would need to enroll 100 participants in each arm to detect our targeted protective efficacy with 80% power at 95% significance (two-sided), allowing for 10% loss to follow-up.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.01</p_value>
            <method>Negative Binomial Regression</method>
            <param_type>Protective Efficacy (%)</param_type>
            <param_value>28</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7</ci_lower_limit>
            <ci_upper_limit>44</ci_upper_limit>
            <estimate_desc>The no chemoprevention arm is the reference arm.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The sample size was calculated to detect at least a 32% lower incidence of malaria in the DP arm compared to that in the TS arm. We assumed that the incidence of malaria would be 1.85 episodes per person-year with TS chemoprevention based on a prior cohort study in the same area, and thus we calculated that we would need to enroll 100 participants in each arm to detect our targeted protective efficacy with 80% power at 95% significance (two-sided), allowing for 10% loss to follow-up.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Negative Binomial Regression</method>
            <param_type>Protective Efficacy (%)</param_type>
            <param_value>58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>45</ci_lower_limit>
            <ci_upper_limit>67</ci_upper_limit>
            <estimate_desc>The no chemoprevention arm is the reference arm.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incident Malaria Cases Per Person Year at Risk in HIV-exposed Participants</title>
        <description>The primary outcome was the incidence of malaria, defined as the number of incident episodes per time at risk, during the period the intervention was given. Treatments within 14 days of a prior episode were not considered incident events. Time at risk was from the day following the initiation of study drugs to the last day of observation, minus 14 days after each treatment for malaria.</description>
        <time_frame>Randomization to 24 months of age</time_frame>
        <group_list>
          <group group_id="O1">
            <title>HIV-exposed &amp; no Chemoprevention</title>
            <description>HIV-exposed No chemoprevention was given</description>
          </group>
          <group group_id="O2">
            <title>HIV-exposed &amp; Monthly SP</title>
            <description>HIV-exposed sulfadoxine-pyrimethamine (SP): monthly dosing given as a single dose, 500mg/25mg tabs</description>
          </group>
          <group group_id="O3">
            <title>HIV-exposed &amp; Daily TS</title>
            <description>HIV-exposed trimethoprim-sulfamethoxazole (TS; TMP/SMX): daily dosing, 20mgTMP/100mgSMX tabs, 80mgTMP/400mgSMX tabs</description>
          </group>
          <group group_id="O4">
            <title>HIV-exposed &amp; Monthly DP</title>
            <description>HIV-exposed dihydroartemisinin-piperaquine (DP): monthly dosing given once a day for 3 consecutive days, 40mg/320mg tabs</description>
          </group>
        </group_list>
        <measure>
          <title>Incident Malaria Cases Per Person Year at Risk in HIV-exposed Participants</title>
          <description>The primary outcome was the incidence of malaria, defined as the number of incident episodes per time at risk, during the period the intervention was given. Treatments within 14 days of a prior episode were not considered incident events. Time at risk was from the day following the initiation of study drugs to the last day of observation, minus 14 days after each treatment for malaria.</description>
          <units>Episodes per person year at risk</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="46"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Randomization - 24 mo. of Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.28"/>
                    <measurement group_id="O2" value="4.50"/>
                    <measurement group_id="O3" value="2.86"/>
                    <measurement group_id="O4" value="1.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Randomization -16 mo. of Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.42"/>
                    <measurement group_id="O2" value="3.72"/>
                    <measurement group_id="O3" value="1.70"/>
                    <measurement group_id="O4" value="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>17-24 mo. of Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.04"/>
                    <measurement group_id="O2" value="5.22"/>
                    <measurement group_id="O3" value="3.79"/>
                    <measurement group_id="O4" value="2.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>We assumed that the incidence of malaria would be 1.85 episodes per person year with TS based on a prior cohort study in the same area, and thus, that we would need to enroll 50 participants in each arm to detect a reduction in the incidence of malaria in either the monthly SP or DP arms (two-sided significance level 0.05) compared with the daily TS arm of 48% or greater with 80% power at 95% significance (two-sided), allowing for 10% loss to follow-up.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.065</p_value>
            <method>Negative Binomial Regression</method>
            <param_type>Protective Efficacy (%)</param_type>
            <param_value>9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-35</ci_lower_limit>
            <ci_upper_limit>38</ci_upper_limit>
            <estimate_desc>The no chemoprevention arm is the reference arm.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>We assumed that the incidence of malaria would be 1.85 episodes per person year with TS based on a prior cohort study in the same area, and thus, that we would need to enroll 50 participants in each arm to detect a reduction in the incidence of malaria in either the monthly SP or DP arms (two-sided significance level 0.05) compared with the daily TS arm of 48% or greater with 80% power at 95% significance (two-sided), allowing for 10% loss to follow-up.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <p_value_desc>Adjusted for age at randomization and incidence of malaria prior to randomization.</p_value_desc>
            <method>Negative Binomial Regression</method>
            <param_type>Protective Efficacy (%)</param_type>
            <param_value>49</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>23</ci_lower_limit>
            <ci_upper_limit>66</ci_upper_limit>
            <estimate_desc>Adjusted for age at randomization and incidence of malaria prior to randomization. The no chemoprevention arm is the reference arm.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>We assumed that the incidence of malaria would be 1.85 episodes per person year with TS based on a prior cohort study in the same area, and thus, that we would need to enroll 50 participants in each arm to detect a reduction in the incidence of malaria in either the monthly SP or DP arms (two-sided significance level 0.05) compared with the daily TS arm of 48% or greater with 80% power at 95% significance (two-sided), allowing for 10% loss to follow-up.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Adjusted for age at randomization and incidence of malaria prior to randomization.</p_value_desc>
            <method>Negative Binomial Regression</method>
            <param_type>Protective Efficacy (%)</param_type>
            <param_value>69</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>53</ci_lower_limit>
            <ci_upper_limit>80</ci_upper_limit>
            <estimate_desc>Adjusted for age at randomization and incidence of malaria prior to randomization. The no chemoprevention arm is the reference arm.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The adverse event data was collected in the time period between randomization and when intervention was stopped (24 mo. of Age).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>HIV-unexposed &amp; no Chemoprevention</title>
          <description>HIV-unexposed No chemoprevention was given</description>
        </group>
        <group group_id="E2">
          <title>HIV-unexposed &amp; Monthly SP</title>
          <description>HIV-unexposed sulfadoxine-pyrimethamine (SP): monthly dosing given as a single dose, 500mg/25mg tabs</description>
        </group>
        <group group_id="E3">
          <title>HIV-unexposed &amp; Daily TS</title>
          <description>HIV-unexposed trimethoprim-sulfamethoxazole (TS; TMP/SMX): daily dosing, 20mgTMP/100mgSMX tabs, 80mgTMP/400mgSMX tabs</description>
        </group>
        <group group_id="E4">
          <title>HIV-unexposed &amp; Monthly DP</title>
          <description>HIV-unexposed dihydroartemisinin-piperaquine (DP): monthly dosing given once a day for 3 consecutive days, 40mg/320mg tabs</description>
        </group>
        <group group_id="E5">
          <title>HIV-exposed &amp; no Chemoprevention</title>
          <description>HIV-exposed No chemoprevention was given</description>
        </group>
        <group group_id="E6">
          <title>HIV-exposed &amp; Monthly SP</title>
          <description>HIV-exposed sulfadoxine-pyrimethamine (SP): monthly dosing given as a single dose, 500mg/25mg tabs</description>
        </group>
        <group group_id="E7">
          <title>HIV-exposed &amp; Daily TS</title>
          <description>HIV-exposed trimethoprim-sulfamethoxazole (TS; TMP/SMX): daily dosing, 20mgTMP/100mgSMX tabs, 80mgTMP/400mgSMX tabs</description>
        </group>
        <group group_id="E8">
          <title>HIV-exposed &amp; Monthly DP</title>
          <description>HIV-exposed dihydroartemisinin-piperaquine (DP): monthly dosing given once a day for 3 consecutive days, 40mg/320mg tabs</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="99"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="46"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="47"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="19" subjects_affected="15" subjects_at_risk="98"/>
                <counts group_id="E2" events="45" subjects_affected="20" subjects_at_risk="98"/>
                <counts group_id="E3" events="20" subjects_affected="14" subjects_at_risk="99"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="98"/>
                <counts group_id="E5" events="19" subjects_affected="8" subjects_at_risk="46"/>
                <counts group_id="E6" events="17" subjects_affected="11" subjects_at_risk="46"/>
                <counts group_id="E7" events="6" subjects_affected="4" subjects_at_risk="47"/>
                <counts group_id="E8" events="6" subjects_affected="5" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="98"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="98"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated temperature</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="98"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated ALT (SGPT)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Elevated AST (SGOT)</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="99"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="98"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Septicemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Poor feeding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="98"/>
                <counts group_id="E2" subjects_affected="66" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="58" subjects_at_risk="99"/>
                <counts group_id="E4" subjects_affected="49" subjects_at_risk="98"/>
                <counts group_id="E5" subjects_affected="28" subjects_at_risk="46"/>
                <counts group_id="E6" subjects_affected="28" subjects_at_risk="46"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="47"/>
                <counts group_id="E8" subjects_affected="14" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="39" subjects_affected="31" subjects_at_risk="98"/>
                <counts group_id="E2" events="44" subjects_affected="28" subjects_at_risk="98"/>
                <counts group_id="E3" events="28" subjects_affected="21" subjects_at_risk="99"/>
                <counts group_id="E4" events="19" subjects_affected="17" subjects_at_risk="98"/>
                <counts group_id="E5" events="18" subjects_affected="14" subjects_at_risk="46"/>
                <counts group_id="E6" events="15" subjects_affected="11" subjects_at_risk="46"/>
                <counts group_id="E7" events="4" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E8" events="10" subjects_affected="7" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="98"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="98"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="98"/>
                <counts group_id="E2" events="12" subjects_affected="7" subjects_at_risk="98"/>
                <counts group_id="E3" events="8" subjects_affected="5" subjects_at_risk="99"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="6" subjects_affected="5" subjects_at_risk="46"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Elevated temperature</sub_title>
                <counts group_id="E1" events="77" subjects_affected="53" subjects_at_risk="98"/>
                <counts group_id="E2" events="75" subjects_affected="49" subjects_at_risk="98"/>
                <counts group_id="E3" events="58" subjects_affected="41" subjects_at_risk="99"/>
                <counts group_id="E4" events="46" subjects_affected="32" subjects_at_risk="98"/>
                <counts group_id="E5" events="22" subjects_affected="17" subjects_at_risk="46"/>
                <counts group_id="E6" events="27" subjects_affected="19" subjects_at_risk="46"/>
                <counts group_id="E7" events="10" subjects_affected="9" subjects_at_risk="47"/>
                <counts group_id="E8" events="8" subjects_affected="6" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated ALT (SGPT)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="98"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="98"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="99"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Elevated AST (SGOT)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="98"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="98"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="46"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E8" events="2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Septicemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="46"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Grant Dorsey</name_or_title>
      <organization>University of California, San Francisco</organization>
      <phone>415-206-4680</phone>
      <email>grant.dorsey@ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

